PRESSR: The 9th Annual GCC Pharmaceutical Regulatory Affairs Summit 2024
First published: 23-Apr-2024 10:09:34
20 billion US dollars is the estimated pharmaceutical market growth and reach in the GCC region.
Dubai, UAE – (ARAB NEWSWIRE) — Themed "Navigate Pharma Regulations with ease & Amplify Commercial Success”, pharmaceutical regulatory authorities and industry leaders convened at the 9th Annual GCC Pharmaceutical Regulatory Affairs Summit in Mövenpick Grand Al Bustan - Dubai, UAE in Dubai, United Arab Emirates, on 22 nd & 23rd of April 2024. The summit brought together over 400+ professionals from both regional and international sectors, featuring more than 55 prominent speakers. The summit also featured expert-lead trainings in pharmacovigilance and eCTD, and it also included two main events, which were the Medical Tender & Business Talk and the GCC Quality Conference.
Esteemed representatives from the Ministry of Health Qatar, the National Health Regulatory Authority (NHRA) in Bahrain, Ministry of Health in Oman, Ministry of Health Iraq, Egyptian Drug Authority, A National Agency of Pharmaceutical Products (ANPP) Algeria, and Jordan Food and Drug Admiration (JFDA), provided comprehensive updates on pharmaceutical regulations and advancements in the industry, within their individual presentation and in-depth panel discussions.
UAE has become a regional hub for the pharmaceutical industry over the past decade and created an environment conducive to sustainable growth. The local market value in UAE is estimated to reach $4.7 billion by 2025 with a growth rate of 27%.
Dr. Mona Al Moussli, Co-Founder and Managing Director of PRA Consultancy, highlighted “It is of high importance to promote awareness regarding pharmaceutical regulations and compliance to sustain Pharmaceutical industry growth.”
The summit featured discussions on innovative practices, including topics such as National and Regional Regulatory Updates, Harmonization, Track and Trace, Orphan Drugs, Digitization, Pharma Manufacturing, Reliance and more. Additionally, the event included the announcement of the GCC Pharma Regulatory Awards 2024, recognizing excellence in regulatory & pharmacovigilance practices.
Dr. Najiba Al Shezawy, Co-Founder and Managing Director of PRA Consultancy commended that “The GCC's commitment to maintaining healthcare standards, particularly in light of recent global challenges.” She adds: A robust pharmaceutical regulations contribute significantly to the region's exemplary healthcare infrastructure.”
Summit attendees networked extensively & joined roundtable discussions with health regulators, fostering knowledge exchange and collaboration.
Send us your press releases to pressrelease.zawya@lseg.com© Press Release 2024
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.